You are here: vision-research.eu » Vision Research » Vision in the European Focus » Grant adressing the Optimal Treatment Approach to Sub-Macular Haemorrhage

Grant adressing the Optimal Treatment Approach to Sub-Macular Haemorrhage

In collaboration with Fight for Sight, EURETINA have launched a call for applications for clinical research to address the best treatment option for Sub-Macular Haemorrhage caused by Age-Related Macular Degeneration.

Age-related macular degeneration (AMD) is the most common cause of severe visual impairment in older adults in the developed world.

Sub-macular haemorrhage (SMH) is caused by damage to the blood vessels and is a severe complication in some cases of exudative AMD. Several treatments have been developed that move the haemorrhage away from the macula, allowing surgeons to have access for treatment. These include displacement therapy, as well as gas and injection combination therapy, but the procedure carries significant risk of complications as well as a high health care cost.

Recent publications have shown that anti-VEGF monotherapy could be compatible with the resolution of SMH and improve visual function. However, to date, no statistically powered randomised control trial has shown which available treatment option is superior.

The aim of this research call is to support and develop the medical management of SMH. Applications are invited from suitably qualified senior principal investigators with a demonstrable track record in conducting and managing large multi-centre ophthalmology trials.

The EURETINA / Fight for Sight SMH Clinical Research Grant provides funding of up to €2,000,000 for a duration of between 3 and 4 years to comprehensively address the optimal treatment approach to sub-macular haemorrhage. The Proposal Instructions contain additional criteria and conditions that applicants should consult during their application.

Fight for Sight is a member of the Association of Medical Research Charities (AMRC) and complies with its guidelines for best practice. Fight for Sight passed the AMRC’s 2015 Peer Review Audit.

Additional criteria are set out in the “Proposal Instructions

  • Applicants must have a tenured post at a recognised university, hospital or research institute within the European Union or H2020 “associated countries” namely, Switzerland, Iceland, Norway, Israel, Turkey, Moldova, Faroe Islands, Ukraine, Tunisia, Georgia, Albania, Bosnia & Herzegovina, the former Yugoslav Republic of Macedonia, Montenegro, Serbia and Armenia.
  • Applicants, including their key clinical research team members, must have a contract of full-time employment which extends beyond the termination date of the Grant.
  • Applicants should be able to demonstrate prior experience and expertise in having previously conducted a clinician-led or industry RCT, or have access to a clinical trials unit within their institution with demonstrable experience in running similar studies.
  • The proposal should demonstrate the clinical importance of the research to the European and global, population, and be broadly translational with the objective of providing a comprehensive evidence base from which a clinical guideline may be produced in due course.
  • The Grant is a purely clinical research funding initiative for the conduct of clinical research in human participants meeting relevant inclusion and exclusion criteria. No animal work should proposed as part of the project

Deadlines & Grant Assessment Panel

The call for the EURETINA / Fight for Sight SMH Clinical Research Grant is now open. The closing date for submissions is 18.00 (CET) on October 31st, 2018. Application must be submitted via our online system grants.fightforsight.org.uk. Late applications will not be considered.

The Grants Assessment Panel

Grants are made on a fully competitive and peer reviewed basis. Fight for Sight is a member of the Association of Medical Research Charities (AMRC) and complies with its guidelines for best practice. EURETINA and Fight for Sight reserve the right to not award any grant funding if none of the submitted applications are deemed to be of sufficient quality. No correspondence will be entered into in relation to grant decisions.

More information under http://www.euretina.org/research-grant/